Table 13.6d
Immunosuppression Use for Maintenance by Regimen
Prior to Discharge, 1996 to 2005
Recipients with Heart-Lung Transplants

	Transplant Year									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Functioning Graft at Discharge	28	40	31	34	33	21	22	17	34	27
With Immunosuppression Info	25	38	29	33	33	21	22	17	34	27
--- + OtherAntimet + Steroids	12.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Steroids	0.0%	0.0%	0.0%	0.0%	0.0%	4.8%	0.0%	0.0%	0.0%	0.0%
CyA	0.0%	0.0%	3.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + MMF/MPA	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + MMF/MPA + Steroids	8.0%	15.8%	24.1%	30.3%	36.4%	33.3%	22.7%	17.6%	17.6%	7.4%
CyA + OtherAntimet	8.0%	5.3%	6.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Steroids	40.0%	39.5%	24.1%	18.2%	33.3%	38.1%	27.3%	23.5%	14.7%	37.0%
CyA + Steroids	4.0%	2.6%	10.3%	12.1%	3.0%	0.0%	0.0%	0.0%	2.9%	0.0%
Tac	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	5.9%	0.0%	0.0%
Tac + MMF/MPA + Steroids	8.0%	2.6%	10.3%	18.2%	9.1%	19.0%	18.2%	5.9%	32.4%	44.4%
Tac + OtherAntimet + Steroids	4.0%	23.7%	13.8%	6.1%	6.1%	4.8%	18.2%	29.4%	14.7%	3.7%
Tac + Siro/Evero + Steroids	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.9%	0.0%
Tac + Steroids	8.0%	2.6%	3.4%	3.0%	3.0%	0.0%	4.5%	11.8%	11.8%	3.7%
Other Regimen	4.0%	7.9%	3.4%	12.1%	9.1%	0.0%	9.1%	5.9%	2.9%	3.7%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Percentages in each column sum to 100 percent.
---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.
MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.
"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.